Messer Laurel H, Bauza Colleen, Miller Kellee M, Clements Mark A, DeSalvo Daniel J, Sherr Jennifer, Weinstock Ruth S, Hood Korey, Laffel Lori M
Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus (now with Tandem Diabetes Care), Aurora, CO, USA.
Jaeb Center for Health Research, Tampa, FL, USA.
Pediatr Diabetes. 2023 Sep 15;2023:6906023. doi: 10.1155/2023/6906023. eCollection 2023.
To evaluate patterns of continuous glucose monitor (CGM) use and perceptions of quality of life in adolescents/young adults with type 1 diabetes (T1D) after using CGM for up to 52 weeks in the CGM Intervention in Teens and Young (CITY) Adults randomized clinical trial (RCT). . Participants with T1D were initially randomized 1 : 1 to use of CGM or blood glucose meter (BGM) for 26 weeks. Following the RCT, participants in the BGM group initiated CGM (BGM-CGM cohort) and participants in the CGM group continued CGM (CGM-CGM cohort) for another 26 weeks. Problem Areas in Diabetes Survey-Pediatric Version (PAID-peds), Glucose Monitoring Satisfaction Survey (GMSS), Hypoglycemia Confidence Scale (HCS), Diabetes Technology Attitudes (DTA), Pittsburgh Sleep Quality Index (PSQI), Benefits of CGM, and Burdens of CGM were completed at baseline, 26 and 52 weeks.
In both cohorts, >70% of participants were wearing CGM > 5 days/week at 52 weeks; 5% discontinued CGM. The majority used the mobile app to receive glucose data. Adolescents (14 to <19 years) were more likely to use SHARE features than young adults (80% versus 41%). CGM-CGM participants had significantly higher scores on GMSS, DTA, and HCS at 52 weeks compared with baseline, and reported higher benefit and lower burden perceptions than at baseline. Similar results were observed for the BGM-CGM cohort.
Improvements in self-reported measures were observed in adolescents and young adults using CGM. As CGM use is also associated with better glycemic control, utilizing CGM may contribute to improving both medical outcomes and emotional health.
在青少年和青年成人1型糖尿病（T1D）患者中开展的持续葡萄糖监测（CGM）干预青少年和青年成人（CITY）成人随机临床试验（RCT）中，评估使用CGM长达52周后青少年/T1D青年成人使用CGM的模式以及对生活质量的认知。患有T1D的参与者最初按1∶1随机分组，分别使用CGM或血糖仪（BGM）26周。RCT结束后，BGM组的参与者开始使用CGM（BGM-CGM队列），CGM组的参与者继续使用CGM（CGM-CGM队列），持续26周。在基线、26周和52周时完成糖尿病调查中的问题领域-儿科版（PAID-peds）、血糖监测满意度调查（GMSS）、低血糖信心量表（HCS）、糖尿病技术态度（DTA）、匹兹堡睡眠质量指数（PSQI）、CGM的益处和CGM的负担等调查。
在两个队列中，52周时超过70%的参与者每周佩戴CGM超过5天；5%的参与者停止使用CGM。大多数人使用移动应用程序接收血糖数据。青少年（14至<19岁）比青年成人更有可能使用共享功能（80%对41%）。与基线相比，CGM-CGM组参与者在52周时GMSS、DTA和HCS得分显著更高，且报告的益处认知更高，负担认知更低。BGM-CGM队列也观察到类似结果。
在使用CGM的青少年和青年成人中，自我报告的指标有所改善。由于使用CGM也与更好的血糖控制相关，使用CGM可能有助于改善医疗结局和情绪健康。
